Certolizumab pegol
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | pegol.html Monografija |
| Identifikatori | |
| CAS broj | 428863-50-7 |
| ATC kod | L04AB05 |
| DrugBank | DB08904 |
| ChEMBL[1] | CHEMBL1201831 
|
| Hemijski podaci | |
| Formula | C2115H3252N556O673S16 |
| Mol. masa | 47.75 kDa |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 14 dana |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Certolizumab pegol je recombinantni Fab' fragment antitela provi faktora nekroze tumora-alfa, koji je konjugovan sa oko 40 kDa polietilen glikola (PEG2MAL40K). Polietilen glikol pomaže u usporavanju metabolizma i eliminacije leka. Hemijski, laki lanac se sastoji od 214 aminokiselina, dok teški lanac ima 229 aminokiselina. Molekulska masa Fab' fragmenta antitela je 47,8 kDa. Ovaj lek se koristi u tretmanu reumatoidnog artritisa i Kronove bolesti. FDA je odobrila ovaj lek u aprilu 2008.[2][3][4][5][6]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948863.
- ↑ Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R: Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013. PMID 23620660
- ↑ Ferrante M, Vermeire S, Rutgeerts P: Certolizumab pegol in the treatment of Crohn's disease. Expert Opin Biol Ther. 2013 Apr;13(4):595-605. doi: 10.1517/14712598.2013.777039. Epub 2013 Mar 4. PMID 23451881
- ↑ https://data.epo.org/publication-server/rest/v1.0/publication-dates/20110803/patents/EP1534753NWB1/document.html
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
